We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
Read MoreHide Full Article
Shares of Dermira, Inc. (DERM - Free Report) have increased by about 5% in the past week, after the FDA approved its Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Primary axillary hyperhidrosis, also commonly known as excessive underarm sweating, is a chronic medical skin condition that results in sweating beyond what is needed for normal body temperature regulation. The approval is based on results from two phase III studies, ATMOS-1 and ATMOS-2. Both trials evaluated the absolute change from baseline in sweat production with Qbrexza use and determined the proportion of patients who achieved at least a 4-point improvement from baseline on the Axillary Sweating Daily Diary instrument.
The news also comes as a respite for Dermira, as in March 2018 the company’s investigational treatment olumacostat glasaretil did not meet the co-primary endpoints in its two phase III studies (CLAREOS-1 and CLAREOS-2) in patients aged nine years and older with moderate-to-severe acne vulgaris..
The approval will be a big boost for the company’s revenues.
Year to date, shares of the company have decreased 66.9% against the industry’s gain of 3.9%.
Jazz’s earnings per share estimates have moved up from $13.02 to $13.09 for 2018 and from $15.17 to $15.21 for 2019 over the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 3.21%. The stock has rallied 31.1% so far this year.
Aeglea’s loss per share estimates have narrowed from $1.93 to $1.67 for 2018 and from $3.86 to $3.57 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 19.32%. The stock has rallied 88.9% so far this year.
ANI Pharmaceuticals’earnings per share estimates have moved up from $5.54 to $5.70 for 2018 and from $5.72 to $6.15 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 8.69%. The stock has rallied 5.7% so far this year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.
Image: Bigstock
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
Shares of Dermira, Inc. (DERM - Free Report) have increased by about 5% in the past week, after the FDA approved its Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Primary axillary hyperhidrosis, also commonly known as excessive underarm sweating, is a chronic medical skin condition that results in sweating beyond what is needed for normal body temperature regulation. The approval is based on results from two phase III studies, ATMOS-1 and ATMOS-2. Both trials evaluated the absolute change from baseline in sweat production with Qbrexza use and determined the proportion of patients who achieved at least a 4-point improvement from baseline on the Axillary Sweating Daily Diary instrument.
The news also comes as a respite for Dermira, as in March 2018 the company’s investigational treatment olumacostat glasaretil did not meet the co-primary endpoints in its two phase III studies (CLAREOS-1 and CLAREOS-2) in patients aged nine years and older with moderate-to-severe acne vulgaris..
The approval will be a big boost for the company’s revenues.
Year to date, shares of the company have decreased 66.9% against the industry’s gain of 3.9%.
Dermira, Inc. Price
Dermira, Inc. Price | Dermira, Inc. Quote
Zacks Rank & Stocks to Consider
Dermira has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the same space are Jazz Pharmaceuticals Plc. (JAZZ - Free Report) , Aeglea BioTherapeutics, Inc. and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of them carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Jazz’s earnings per share estimates have moved up from $13.02 to $13.09 for 2018 and from $15.17 to $15.21 for 2019 over the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 3.21%. The stock has rallied 31.1% so far this year.
Aeglea’s loss per share estimates have narrowed from $1.93 to $1.67 for 2018 and from $3.86 to $3.57 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 19.32%. The stock has rallied 88.9% so far this year.
ANI Pharmaceuticals’earnings per share estimates have moved up from $5.54 to $5.70 for 2018 and from $5.72 to $6.15 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 8.69%. The stock has rallied 5.7% so far this year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.
See This Ticker Free >>